# Denali Therapeutics (DNLI) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/DNLI
## Company Profile
- Ticker: DNLI
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: MedTech, CNS
## Stock Data
- Close: 24.69 USD
- Market cap: 3071033410.9500003 USD
- Last updated: 2026-08-11
## Business Overview
### Blood-Brain-Barrier Delivery
Denali Therapeutics develops medicines for neurodegenerative and lysosomal-storage diseases. Its TransportVehicle platform uses transferrin-receptor binding to carry enzymes, proteins and oligonucleotides across the blood-brain barrier.
### AVLAYAH
AVLAYAH, or tividenofusp alfa, is an enzyme TransportVehicle therapy approved for neurologic manifestations of Hunter syndrome in selected pediatric patients. It is the first commercial validation of Denali's delivery platform.
### DNL593
DNL593 is a progranulin replacement therapy delivered with the protein TransportVehicle for GRN-related frontotemporal dementia.
### DNL628
DNL628 is an oligonucleotide TransportVehicle candidate designed to reduce tau production in Alzheimer's disease through systemically delivered genetic medicine.
### DNL126
DNL126 is an enzyme TransportVehicle replacement therapy for Sanfilippo syndrome type A, intended to address neurologic and systemic manifestations of the lysosomal-storage disease.
## Why The Stock Is Moving

As of Aug 11, 2026, DNLI closed down 1.24% at $24.69. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 1/2 data for DNL593 in GRN-related frontotemporal dementia by the end of 2026.

## Recent News
- 2026-08-06 20:01 EST — [Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-second-quarter-2026-financial-results-and-business-h-04a0e77e) — Source: Denali Therapeutics
- 2026-07-27 20:01 EST — [Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026](https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-report-second-quarter-2026-financial-results-and-business-55ac999b) — Source: Denali Therapeutics
- 2026-07-09 20:01 EST — [Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier](https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-give-opening-plenary-address-at-alzheimer-s-association-i-4deb6898) — Source: Denali Therapeutics
- 2026-06-18 12:00 EST — [Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million](https://biopharmsignal.com/news/DNLI/denali-therapeutics-enters-agreement-to-sell-rare-pediatric-disease-priority-rev-0e62f7af) — Source: Denali Therapeutics
- 2026-05-21 22:00 EST — [Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease](https://biopharmsignal.com/news/DNLI/biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122--cfdf22fe) — Source: Denali Therapeutics